✦ LIBER ✦

Aggregation kinetics of recombinant human FVIII (rFVIII)

✍ Scribed by Karthik Ramani; Vivek Purohit; C. Russell Middaugh; Sathyamangalam V. Balasubramanian

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 119 KB
Volume: 94
Category: Article
ISSN: 0022-3549
DOI: 10.1002/jps.20432

No coin nor oath required. For personal study only.

✦ Synopsis

The physical phenomenon of aggregation can have profound impact on the stability of therapeutic proteins. This study focuses on the aggregation behavior of recombinant human FVIII (rFVIII), a multi-domain protein used as the first line of therapy for hemophilia A, a bleeding disorder caused by the deficiency or dysfunction of factor VIII (FVIII). Thermal denaturation of rFVIII was investigated using circular dichroism (CD) spectroscopy and size exclusion chromatography (SEC). The dependence of unfolding on heating rate indicated that the thermal denaturation of the protein was at least partly under kinetic control. The data was interpreted in terms of a simple two-state kinetic model, NðNativeÞ À! k AðAggregatedÞ, where k is a first-order kinetic constant that changes with temperature, as given by the Arrhenius equation. Analysis of the data in terms of the above scheme suggested that under the experimental conditions used in this study, the rate-controlling step in the aggregation of rFVIII may be a unimolecular reaction involving conformational changes.

📜 SIMILAR VOLUMES

Lipid binding region (2303–2332) is invo

Lipid binding region (2303–2332) is involved in aggregation of recombinant human FVIII (rFVIII)

✍ Karthik Ramani; Vivek S. Purohit; Razvan D. Miclea; C. Russell Middaugh; Sathyam 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB

Factor VIII (FVIII) is a multi-domain protein that is important in the clotting cascade. Its deficiency causes Hemophilia A, a bleeding disorder. The unfolding of protein domains can lead to physical instability such as aggregation, and hinder their use in replacement therapy. It has been shown that

Population balance modeling of aggregati

Population balance modeling of aggregation kinetics of recombinant human interleukin-1 receptor antagonist

✍ Eva Y. Chi; Brent S. Kendrick; John F. Carpenter; Theodore W. Randolph 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 230 KB

The kinetics of benzyl alcohol-induced nonnative aggregation of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) were investigated using a population balance model. Steady-state size distributions of rhIL-1ra aggregates formed in a continuous mixed suspension, mixed product removal (MS

High concentration formulations of recom

High concentration formulations of recombinant human interleukin-1 receptor antagonist: II. aggregation kinetics

✍ John R. Alford; Brent S. Kendrick; John F. Carpenter; Theodore W. Randolph 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB

At high protein concentrations (i.e., 50-100 mg/mL) and 378C, low solution ionic strength accelerates aggregation of recombinant human interleukin-1 receptor antagonist (rhIL-1ra). We have used a variety of physical and spectroscopic techniques to explain this observation. A population balance model

Kinetics of aggregation of human platele

Kinetics of aggregation of human platelets

✍ Anwar B. Bikhazi; Ghassan E. Ayyub 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 710 KB

Aggregation of recombinant human botulin

Aggregation of recombinant human botulinum protein antigen serotype c in varying solution conditions: Implications of conformational stability for aggregation kinetics

✍ Shujun Bai; Mark Cornell Manning; Theodore W. Randolph; John F. Carpenter 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 460 KB

Solution conditions greatly affect the aggregation rate of a protein. Elucidating these influences provides insight into the critical factors governing aggregation. In this study, recombinant human botulinum protein antigen serotype C [rBoNTC (H(c))] was employed as a model protein. rBoNTC (H(c)) ag

Phosphatidylserine containing liposomes

Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A

✍ Karthik Ramani; Razvan D. Miclea; Vivek S. Purohit; Donald E. Mager; Robert M. S 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB

Factor VIII (FVIII) is a multidomain protein that is deficient in hemophilia A, a clinically important bleeding disorder. Replacement therapy using recombinant human FVIII (rFVIII) is the main therapy. However, approximately 15-30% of patients develop inhibitory antibodies that neutralize rFVIII act